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Abstract
Objectives: This protocol outlines a systematic review methodology, aiming to assess the recent evidence-base for
the impact of testing strategies and approaches on access to testing, testing coverage, and linkage to care for
populations at risk for specific curable sexually transmitted infections (STIs) (chlamydia, gonorrhoea, syphilis,
trichomoniasis, and Mycoplasma genitalium infections).
Data sources: These include MEDLINE, Embase, PsycINFO, Global Health, Cochrane Database, Epistemonikos,
CINAHL Plus, and Web of Science Core Collection.
Review methods: Papers reporting primary data from 1 January 2012 onwards will be included. Titles, abstracts,
and full texts will be reviewed for inclusion, and data will be extracted using a pre-specified and piloted data
extraction form, by two independent reviewers. Experts in the field will be contacted and interviewed for further
information about ongoing or unpublished studies. A narrative synthesis of the findings will be conducted.
Discussion: Outcomes of this study will inform policy makers, national and international programme coordinators,
public health and clinical experts, and civil society organisations involved in STI prevention and control in EU/EEA
countries and elsewhere. The review will provide a direction for future researchers and programmers seeking to
improve STI testing services among key populations at high risk for STIs.
Systematic review registration: In accordance with guidelines outlined in the PRISMA-P methodology, this
protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO) on 30
January 2019: CRD42019118261.
Keywords: Sexually transmitted infections, Chlamydia trachomatis, Neisseria gonorrhoeae, Treponema pallidum,
Mycoplasma genitalium, Trichomonas vaginalis, Trichomoniasis, Gonorrhoea, syphilis, Diagnostic test, Coverage,
Linkage to care, Access
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Background
In 2016, there were an estimated 376.4 million new cases
of the four most common curable sexually transmitted
infections (STIs) worldwide: chlamydia (127.2 million
cases), gonorrhoea (86.9 million cases), syphilis (6.3 mil-
lion cases), and trichomoniasis (156.0 million cases) [1].
These infections have a profound impact on the health
and wellbeing of people worldwide, including foetal and
neonatal deaths, infertility, increased human immuno-
deficiency virus (HIV) transmission risk, and psycho-
logical and social consequences [2].
Compared to other regions, the prevalence and inci-
dence of the four curable STIs in the World Health
Organization (WHO) European Region were among the
lowest, yet, there was substantial burden of STIs in Eur-
ope, the highest being chlamydia [3]. The 2017 European
Union/European Economic Area (EU/EEA) surveillance
data reflect WHO estimates and show that chlamydia,
despite a large inter-country variation in testing and no-
tification of cases, is the most frequently reported STI in
Europe (409,646 cases; a notification rate of 146 per 100,
000 population) followed by gonorrhoea (76,076 cases;
22 per 100,000 population) and syphilis (33,193 cases; 7
per 100,000 population) [4]. In addition, these data indi-
cate that several sub-populations, including young
people (15–24 years old), men who have sex with men
(MSM), and sex workers (SW), are disproportionally di-
agnosed with bacterial STIs. Pregnant women from sev-
eral vulnerable groups, such as migrant women and
women exercising high-risk behaviours (injection drug
use, sex work, etc.) were identified as at risk of adverse
pregnancy outcomes due to STIs and poor access to
antenatal care [5]. In addition to chlamydia, gonorrhoea,
and syphilis, trichomoniasis and Mycoplasma genitalium
are important and under-recognised causes of poor sex-
ual health [6–8]. Poor outcomes related to curable STIs
are preventable if timely and effective testing and treat-
ment are implemented.
New testing technologies, strategies, and approaches
may lead to increased coverage and enhanced delivery of
public health function which would improve the preven-
tion and control in populations most at risk for STIs.
For example, rapid point-of-care tests can pave the way
for decentralised STI testing including self-sampling and
self-testing outside of traditional healthcare settings,
including community-based organisations, pharmacies,
and at home [9]. While more recent testing technologies,
such as point-of-care tests, can provide faster and more
flexible STI testing, they must be paired with innovative
strategies and approaches for reaching populations most
at risk for STIs. Indeed, innovative strategies and ap-
proaches may even utilise older technologies to increase
testing access and coverage in these populations, such as
a community-based approach to STI testing using a
strategy of providing samples that can be self-collected
and sent by post (or sample drop off locations) to an
STI laboratory.
In 2012, the European Centre for Disease Prevention
and Control (ECDC) published the technical report
“Novel approaches to testing for sexually transmitted in-
fections, including HIV and hepatitis B and C in Europe”
[10]. This report was a comprehensive but non-
systematic review of testing technologies and strategies
across Europe, the USA, Canada, and Australia. It
focused on the expansion of existing technology, and
new technologies, such as point-of-care tests. There have
been several other recent reviews on point-of-care tests,
including the WHO Point-of-Care Diagnostic Landscape
for STIs detailing the pipeline which is updated regularly
[11–13]. The ECDC report also reviewed strategies to
increase testing such as self-testing and testing through
community settings, and communication of results using
mHealth strategies such as SMS texting. Six years later,
the aim of this review is to systematically review the lit-
erature and synthesise the results of studies implement-
ing recent strategies and approaches in populations to
improve access to testing, coverage of testing, and link-
age to care. Therefore, the aim is not to review testing
technologies in the pipeline (technologies in develop-
ment and evaluation prior to their routine use in prac-
tice), but to gather evidence of the impact of strategies
and approaches, including new testing technologies, that
are currently being used. This review includes publica-
tions worldwide from 2012 onwards to capture recent
strategies and approaches that could include new testing
technologies reviewed earlier, and a narrowed scope to
curable bacterial and parasitic STIs, as developments for
testing HIV and hepatitis B and C were recent sum-
marised in the ECDC’s public heath guidance [14]. Add-
itionally, it requires studies to have a comparison group
to be able to show a quantifiable impact of the strategies
and approaches.
The primary research question of this review is “What
is the impact of testing strategies and approaches that
have been published since 2012, on access to testing,
testing coverage and linkage to care for specific curable
STIs (chlamydia, gonorrhoea, syphilis, trichomoniasis
and Mycoplasma genitalium infection)?” The research
question was formulated using the Population, Interven-
tion, Comparison and Outcome (PICO) framework [15]
(Table 1), with advice from the Novel Approaches and
Strategies for STIs (NASSTI) project Advisory Commit-
tee. Secondary research questions are what testing tech-
nologies are used in these strategies and approaches to
impact on access to testing, testing coverage, and linkage
to care and what is the impact of testing technologies,
strategies, and approaches on STI public health surveil-
lance programmes? For example, they could lead to
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increased coverage and accuracy of country-level STI
surveillance, earlier and more accurate diagnosis, and
strengthened management and control programmes.
Methods
This systematic review protocol describes the approach
to reviewing and synthesising the literature to answer
the research questions. The search has been designed
based on the primary research question; therefore, the
data for the secondary research questions will be limited
to this search strategy. In addition, experts in the field
identified from the review process and other researchers
who have previously worked on the topic, including the
NASSTI Advisory Committee members will be con-
tacted and interviewed for further information about on-
going or unpublished studies. This protocol is reported
as per the Preferred Reporting Items for Systematic Re-
views and Meta-Analyses Protocol (PRISMA-P) checklist
[16] (Additional file 1). At the time of submission of this
protocol for publication in April 2019, the search strat-
egy had been finalised and was completed in November
2018, and title and abstract screening were underway.
Search strategy
The following databases were searched: MEDLINE
(OvidSP interface); Embase (OvidSP interface); Psy-
cINFO (OvidSP interface); Global Health (OvidSP inter-
face); Cochrane Library including Cochrane Database of
Systematic Reviews, the Cochrane Central Register of
Controlled Trials (CENTRAL) and Cochrane Clinical
Answers (Wiley interface); Epistemonikos (Epistemoni-
kos interface); CINAHL Plus (Ebsco interface); and the
Web of Science Core Collection (Web of Science inter-
face). The search was restricted to works published after
1st January 2012 as the previous ECDC report [10]
included publications until that date. Language or
geographical restrictions were not added to the search;
however, studies from outside the EU/EEA or
Switzerland reported in a non-English language will be
excluded during screening. The terms for chlamydia,
gonorrhoea, and syphilis were taken from the Cochrane
STI group systematic review (2012) of topical micro-
bicides for prevention of STIs [17]. Terms for M.
genitalium and trichomoniasis were developed by adapt-
ing the Cochrane STI group strategy for these two infec-
tions. Two librarians were consulted to provide guidance
for searching terms for “testing technologies”, “ap-
proaches”, and “strategies”. The final Medline search
strategy was peer-reviewed by an ECDC librarian not
associated with the project, using the Peer Review of
Electronic Search Strategies (PRESS) standard [18]. The
search was then adapted to meet the thesaurus terms
and syntax of the other databases and published in an
open access data repository (https://doi.org/10.17037/
DATA.00001047). References of included papers will be
hand searched.
Eligibility criteria and study selection
Detailed eligibility criteria are outlined in Table 2 Eli-
gible studies must be original primary research from
studies with a comparison group to show quantifiable
impact (e.g. a comparison of coverage between the inter-
vention and comparison group). Therefore, all peer-
reviewed papers and conference abstracts describing
studies with a comparison group were eligible, but sys-
tematic reviews were excluded. Eligible studies must be
reported in English from any country or any European
language from an EU/EEA country and Switzerland. The
study population will be receivers of STI testing. The in-
terventions included are testing strategies or approaches
of one or more of the five pathogens: C. trachomatis, N.
gonorrhoeae, T. pallidum, M. genitalium, and T. vagina-
lis. The outcomes of interest are improved access to
testing, testing coverage, or linkage to care, which we
have defined using WHO definitions [19] (Table 3). Due
to the broad nature of the review, any comparator will
be eligible for inclusion (e.g. standard practice).
References will be exported into EndNote software
(Clarivate Analytics, Philadelphia, USA) and duplications
removed. Titles, abstracts and full-text screening will be
carried out independently by two reviewers (AA and
AP) with the support of an eligibility criteria screening
tool (Table 4). Titles and abstracts will be scanned to se-
lect full-text articles for in-depth screening. Articles will
be selected for full-text review if both reviewers agree on
eligibility criteria or if the abstract does not provide suf-
ficient information to make a decision. A third reviewer
(EHE or SCF) will arbitrate any discrepancies between
reviewers. Inter-rater agreement will be assessed using
the kappa statistic for each stage of the screening
Data extraction and study quality assessment tool
Data will be extracted from included studies using a pre-
specified extraction form developed using a password
secured online questionnaire (Online Surveys; https://
www.onlinesurveys.ac.uk/). Variables to be extracted
Table 1 PICO framework for identifying studies relevant to the
primary research question
Population All groups at risk for STI
Intervention Testing strategies and approaches used to increase testing
access and coverage and linkage to care for C. trachomatis,
N. gonorrhoeae, T. pallidum, M. genitalium, and T. vaginalis
Comparison Any comparator
Outcome Access to testing
Testing coverage
Linkage to care
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include the following: STI pathogen, study design, size
of the study (e.g. number of participants enrolled), strat-
egy or approach, impact on testing access, coverage, or
linkage to care, population, setting, testing technology,
reporting for surveillance, feasibility and acceptability,
and gaps identified for future research. Additional data
will be extracted to assess the risk of bias at the study
level according to PRISMA guidelines [20]. Well-
established tools will be adapted to assess the risk for
bias. The Cochrane risk of bias tool (Version 1) will be
used to assess randomised controlled trials [15], and the
ROBINS-I tool will be used to assess risk of bias in non-
randomised studies of interventions [21]. The Cochrane
risk of bias tool will be adapted to introduce of an “over-
all bias” summary domain, similar to the ROBINS-I tool,
which will allow comparison between interventional and
non-interventional tools. The ROBINS-I tool will be
simplified from five possible outcomes (“Low risk of
Table 2 Eligibility criteria
Inclusion criteria:
1. Papers from January 2012 to November 2018 (included in search
terms)
2. Papers investigating testing strategies or approaches of one or more
of the five pathogens of interest: C. trachomatis, N. gonorrhoeae, T.
pallidum, M. genitalium, and T. vaginalis (included in search terms)
3. Papers reported in English from any country
4. Papers reported in any European language from an EU/EEA country
and Switzerland
5. Papers reporting primary data
6. Papers reporting on a testing approach or strategy for initial diagnosis
of the index case, with the purpose of improving access to testing,
testing coverage, or linkage to care (e.g. service evaluations)
7. Papers reporting on genital and extra-genital (rectal and pharyngeal)
infections resulting from sexual transmission in patients.
Exclusion criteria:
1. Papers reported in a non-English language outside of the EU/EEA and
Switzerland (e.g. Chinese, Japanese, and Korean, or for example, a paper
reported in French from Senegal)
2. Systematic reviews, guidelines, organisational reports, abstract
booklets, mathematical modelling studies
3. Papers evaluating a testing approach or strategy not for the purpose
of improving access to testing, testing coverage, or linkage to care (e.g.
prevalence study only, diagnostic accuracy study, risk factor/association
studies)
4. Papers evaluating a testing approach or strategy without having a
comparison group
5. Papers evaluating a testing approach or strategy not for the purpose
of initial diagnosis of the index case (e.g. studies on test of cure, partner
notification, or retesting)
6. Papers looking at testing of complications of infection (e.g. pelvic
inflammatory disease (PID), tubal infertility, neurosyphilis)
7. Papers reporting on ocular, pulmonary or other (not pharyngeal or
rectal) extra-genital infection
8. Papers reporting on animal or in vitro infections (e.g. diagnostics used
in the laboratory only)
9. Papers reporting on antimicrobial resistance (AMR) testing only
Table 3 WHO definitions of access, coverage and linkage to
care [16]
Access: “Access is a broad term with varied dimensions: the
comprehensive measurement of access requires a systematic
assessment of the physical, economic, and socio-psychological aspects
of people’s ability to make use of health services.”
Coverage: “Coverage of interventions is defined as the proportion of
people who receive a specific intervention or service among those who
need it.”
Linkage to care: e.g. proportion of infected people treated or referred
for treatment, results reporting to patient, etc.
Table 4 Screening tool for all stages: title, abstract, and full-text
(go from steps 1 to 8)
1. Was this paper published after 1st January 2012?
a. No, exclude.
b. Yes or uncertain, go to step 2
2. Does this paper involve humans?
a. No (animal or in vitro; lab-only diagnostics), exclude.
b. Yes or uncertain, go to step 3
3. Is the paper in English? OR Is the paper in any European language
AND from an EU/EEA country or Switzerland?
a. No, exclude.
b. Yes or uncertain, go to step 4
4. Is the paper reporting primary data?
a. No (systematic reviews, guidelines, organisational reports,
abstract booklets, mathematical modelling studies), exclude
b. Yes, go on to step 5
5. Does this paper assess a genital and extra-genital (rectal and
pharyngeal) sexually transmitted infection?
a. No (other extra-genital, non-sexually transmitted infection – e.g.
trachoma, congenital STIs like congenital syphilis or chlamydial
conjunctivitis or pneumonia), exclude.
b. Yes or uncertain, go to step 6
6. Does this paper focus on testing strategies or approaches for
infections with C. trachomatis, N. gonorrhoeae, T. pallidum, M.
genitalium or T. vaginalis?
a. No (e.g. HIV, HCV, BV, HSV, etc. only), exclude.
b. Yes or uncertain, go to step 7
7. Does this paper assess testing strategies or approaches to improve
access to testing, testing coverage, or linkage to care?
a. No, (e.g. descriptive epidemiology only, risk factor/association
studies, laboratory diagnostic accuracy study, basic science
leading to test development, prevention studies e.g. condom
uptake, counselling, prep), exclude.
b. Yes (e.g., service evaluations) or uncertain, go to step 8.
8. Does this paper assess testing strategies or approaches for initial
diagnosis of the index case?
a. No (e.g. studies on test of cure, partner notification, or retesting),
exclude.
b. Yes or uncertain, go to step 9
9. Does this paper assess testing strategies or approaches for
complications of infection only?
a. Yes (PID, tubal infertility, neurosyphilis, etc.), exclude.
b. No or uncertain, go to step 10
10. Is this paper reporting on AMR testing only e.g. it does not include
diagnosis of the infection itself?
a. Yes, exclude
b. No, include.
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bias”, “Moderate risk of bias”, “Severe risk of bias”, “Crit-
ical risk of bias”, No information) to three outcomes as
suggested in the Cochrane Handbook (+ or “Low risk of
bias”, − or “High risk of bias”, and ? or “Insufficient
Information”)(Additional file 3).
Data will be extracted by two reviewers independently
(AA and AP). Results will be compared and resolved be-
tween the two reviewers, and a third reviewer (EHE or
SCF) will arbitrate any discrepancies between reviewers.
The extraction form will be piloted with five papers to
ensure ease-of-use, that all pertinent data items are in-
cluded, and consistency between reviewers.
Data synthesis and analysis
The final number and characteristics of studies identified
for inclusion in, and exclusion from, the systematic review
will be reported in a PRISMA flow diagram [20]. We will
tabulate all extracted data, including participant character-
istics, study designs, interventions, instruments, and study
results. The data will not be synthesised quantitatively in
the form of a meta-analysis due to the variety in study
methodologies and outcomes anticipated in included
studies. Instead, a systematic narrative synthesis will be
provided with information presented in the text and tables
of the included studies. For the primary research question
(What is the impact of testing strategies and approaches
on access to testing, testing coverage and linkage to care
for curable STIs?), data will be organised by STI, popula-
tion, and outcomes (access to testing, testing coverage and
linkage to care). To address the secondary questions
(testing technologies used; impact on STI public health
surveillance programmes), we will describe the number of
studies that presented data for each of the questions and
present the differences between the study results in a
narrative form. The narrative synthesis will explore the
relationships and findings both within and between the in-
cluded studies in line with the guidance from the Centre
for Reviews and Dissemination [22]. Results from the risk
of bias assessments will be presented in a matrix and will
be used to help interpret and explain differences in results
across studies. As we are not performing a quantitative
synthesis, we will not use statistical methods of assessing
publication bias. The strength of the body of evidence will
not be assessed (e.g. GRADE) due to broad nature of the
research question.
Expert interviews and ethical considerations
After a narrative synthesis has been conducted, gaps
related to the primary and secondary research questions
will be identified by the study team and advisory com-
munity. Expert interviews will be conducted to further
contextualise these gaps with relevant published and
unpublished information provided by the expert. Any
publications provide by experts will be screened for
eligibility. Experts will be identified through the system-
atic literature review and professional networks. Each
expert will be contacted by email, provided with infor-
mation about the systematic review, and invited for an
interview. If interested in participating, the expert will be
asked for written informed consent. All consenting ex-
perts will be interviewed with a semi-structured topic
guide (Additional file 2). Interviews will be held in-
person or by remote telecommunications, as appropri-
ate. Interviews will be audio-recorded with permission
from the expert. For experts who do not consent to
audio recording, detailed notes will be taken. The con-
clusions of each interview will be summarised and sent
to each expert interviewee for written verification.
Ethical approval has been provided by the London
School of Hygiene & Tropical Medicine ethics committee
(reference: 16338).
Discussion
This systematic review will provide an evidence-base for
implementing testing strategies and approaches to in-
crease testing access, coverage, and linkage to care in
populations at risk for STIs in the EU/EEA. The review
will build add to the 2012 ECDC report technical report
"[10], refocusing the review on specific curable STIs and
strategies and approaches used to impact testing access,
testing coverage and linkage to care. The latter shift is to
provide a public heath perspective and inform policy
makers of the approaches and strategies that can be
used, even if new testing technologies cannot be feasibly
implemented. Emerging STI testing technologies (i.e.,
diagnostics) are included as a secondary research ques-
tion only (other reviews exist with this as a primary
objective [11–13, 23, 24]). Additionally, this review will
include studies from outside the EU/EEA as there may
be strategies implemented elsewhere that may be trans-
ferable to the EU/EEA.
The strengths of this systematic review include an in-
depth and well-defined search strategy for the primary
research question applied to a comprehensive set of
databases, no language restrictions for EU/EEA publica-
tions, and input from an advisory committee and expert
interviews to address gaps identified in the search. The
latter will help overcome the main limitation which is
that the primary research question search will be used
for the secondary research questions; therefore, increas-
ing the risk that relevant studies will not be retrieved.
Outcomes of this study will inform policy makers, na-
tional and international programme coordinators, public
health or clinical experts, and civil society organisations
involved in STI prevention and control in EU/EEA coun-
tries and elsewhere. The review will provide a direction
for future researchers and programmers seeking to im-
prove STI testing services for populations at risk for STIs.
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